News & Events

Press Releases

Loading...

End of content

No more pages to load

December 21st, 2021

Agomab Expands Team with Reginald Brys as Head of Research and Maria Nichol as Head of IP

Agomab Therapeutics NV (‘Agomab’) today announced the expansion of its team with two key hires: Reginald Brys will join as Head of Research and Maria Nichol will become Head of Intellectual Property. Each brings more than 20 years of highly valuable experience in identifying and driving novel drug candidate development and international patent law and strategy, respectively.
December 15th, 2021

Agomab Therapeutics Completes Acquisition of Origo Biopharma

Agomab Therapeutics NV (‘Agomab’) announced today the closing of the Origo Biopharma acquisition. The transaction, first announced on October 28th, 2021, combines Spanish biotech Origo Biopharma and its pipeline of organ-restricted small molecule drug candidates targeting the transforming growth factor beta (TGF-β) pathway with Agomab’s hepatocyte growth factor (HGF)-targeting programs.
October 28th, 2021

Agomab Therapeutics to Acquire Origo Biopharma

Agomab Therapeutics NV (‘Agomab’) announced today that it has entered into a definitive agreement under which it will acquire Origo Biopharma S.L., a Spanish clinical-stage biotechnology company developing organ-restricted small molecule drug candidates targeting the transforming growth factor beta (TGF-β) pathway for the treatment of fibrosis-related disorders.

Loading...

End of content

No more pages to load

April 3rd, 2019

AgomAb Therapeutics Completes €21m Series A Financing

AgomAb Therapeutics N.V., a privately held Belgian biotherapeutics company developing agonistic antibodies for regeneration of damaged tissues, announces today that it has secured €21m in a Series A financing round from a strong international investor syndicate.

Loading...

End of content

No more pages to load

December 21st, 2021

Agomab Expands Team with Reginald Brys as Head of Research and Maria Nichol as Head of IP

Agomab Therapeutics NV (‘Agomab’) today announced the expansion of its team with two key hires: Reginald Brys will join as Head of Research and Maria Nichol will become Head of Intellectual Property. Each brings more than 20 years of highly valuable experience in identifying and driving novel drug candidate development and international patent law and strategy, respectively.
December 15th, 2021

Agomab Therapeutics Completes Acquisition of Origo Biopharma

Agomab Therapeutics NV (‘Agomab’) announced today the closing of the Origo Biopharma acquisition. The transaction, first announced on October 28th, 2021, combines Spanish biotech Origo Biopharma and its pipeline of organ-restricted small molecule drug candidates targeting the transforming growth factor beta (TGF-β) pathway with Agomab’s hepatocyte growth factor (HGF)-targeting programs.
October 28th, 2021

Agomab Therapeutics to Acquire Origo Biopharma

Agomab Therapeutics NV (‘Agomab’) announced today that it has entered into a definitive agreement under which it will acquire Origo Biopharma S.L., a Spanish clinical-stage biotechnology company developing organ-restricted small molecule drug candidates targeting the transforming growth factor beta (TGF-β) pathway for the treatment of fibrosis-related disorders.
April 3rd, 2019

AgomAb Therapeutics Completes €21m Series A Financing

AgomAb Therapeutics N.V., a privately held Belgian biotherapeutics company developing agonistic antibodies for regeneration of damaged tissues, announces today that it has secured €21m in a Series A financing round from a strong international investor syndicate.

Loading...

End of content

No more pages to load

Looking to connect with us?

Kempen Private European Life Science Conference
November 28, 2022
Virtual

RBC Capital Markets Healthcare Private Company Conference
December 14-15, 2022
Virtual

JP Morgan Healthcare Private Company Conference
January 9-13, 2023
San Francisco

Events

By continuing to use the site, you agree to the use of cookies. Privacy Policy

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close